================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2009
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
0-15482
----------------------
(Commission File Number)
Nevada 86-1006416
------------------------------ -----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
P.O. Box 8832
Grand Rapids, MI 49518-8832
--------------------------------------
(Address of principal executive offices)
(616) 977-9933
-------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01 - Other Events
By letter dated August 12, 2009, the Securities and Exchange Commission
("SEC") notified us that unless we become current with our required public
filings by August 27, 2009, the SEC may cause the Company to be de-registered
under the securities laws and that the SEC may issue an order suspending public
trading of the Company's securities. As a result of preliminary conversations
with the staff of the SEC, believes that additional time may be granted that
will be sufficient for the Company to be compliant with its filings. However,
there is no assurance of that outcome. Such de-registration and suspension of
trading will seriously limit the ability of investors to re-sell any of our
shares held by them. In June, 2009, we began an effort to achieve compliance
with all reporting requirements and our independent auditors are in the process
of examining our financial statements with a view to certifying them as required
by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: September 14, 2009 ONCOLOGIX TECH, INC.
By: /s/ Anthony Silverman
--------------------------------
Anthony Silverman,
Chief Executive Officer
and President
By: /s/ Michael A. Kramarz
--------------------------------
Michael A. Kramarz,
Chief Financial Officer